JP2000501838A - 細胞生存率、有核赤血球、および白血球分類の同時分析方法 - Google Patents
細胞生存率、有核赤血球、および白血球分類の同時分析方法Info
- Publication number
- JP2000501838A JP2000501838A JP09522287A JP52228797A JP2000501838A JP 2000501838 A JP2000501838 A JP 2000501838A JP 09522287 A JP09522287 A JP 09522287A JP 52228797 A JP52228797 A JP 52228797A JP 2000501838 A JP2000501838 A JP 2000501838A
- Authority
- JP
- Japan
- Prior art keywords
- wbc
- nrbc
- signal
- cell
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 175
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 43
- 238000004458 analytical method Methods 0.000 title description 26
- 230000003833 cell viability Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 65
- 238000000684 flow cytometry Methods 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 91
- 210000004369 blood Anatomy 0.000 claims description 71
- 239000008280 blood Substances 0.000 claims description 71
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- 239000000975 dye Substances 0.000 claims description 30
- 239000012128 staining reagent Substances 0.000 claims description 21
- 238000005259 measurement Methods 0.000 claims description 20
- 230000006378 damage Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 15
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims description 15
- 210000000170 cell membrane Anatomy 0.000 claims description 14
- 238000010186 staining Methods 0.000 claims description 11
- 230000009089 cytolysis Effects 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 5
- 229960005542 ethidium bromide Drugs 0.000 claims description 5
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims description 4
- 210000000601 blood cell Anatomy 0.000 claims description 4
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 230000002101 lytic effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 description 56
- 210000004698 lymphocyte Anatomy 0.000 description 23
- 210000004940 nucleus Anatomy 0.000 description 20
- 238000001514 detection method Methods 0.000 description 17
- 238000000149 argon plasma sintering Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 210000001772 blood platelet Anatomy 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 238000010586 diagram Methods 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 5
- 239000000980 acid dye Substances 0.000 description 5
- 210000003651 basophil Anatomy 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 238000010224 classification analysis Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- OWLJDBBFRJXPGM-VBIGTWTASA-N [(1S,2S,4S,5S,7S,8R,9R,11S,13S)-1-methyl-17-oxo-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl] (2R)-2-amino-3-methylbutanoate Chemical compound [H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)[C@H](N)C(C)C)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C OWLJDBBFRJXPGM-VBIGTWTASA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 238000013394 immunophenotyping Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- BUBBEHCXSMCYNY-CVEARBPZSA-N [3-hydroxy-5-methyl-4-[(2S,3R)-2,3,4-trihydroxybutoxy]carbonylphenyl] 2,4-dihydroxy-6-methylbenzoate Chemical compound CC1=CC(O)=CC(O)=C1C(=O)OC1=CC(C)=C(C(=O)OC[C@H](O)[C@H](O)CO)C(O)=C1 BUBBEHCXSMCYNY-CVEARBPZSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002109 erythrocyte inclusion Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000815 hypotonic solution Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- FGBAVQUHSKYMTC-UHFFFAOYSA-M LDS 751 dye Chemical compound [O-]Cl(=O)(=O)=O.C1=CC2=CC(N(C)C)=CC=C2[N+](CC)=C1C=CC=CC1=CC=C(N(C)C)C=C1 FGBAVQUHSKYMTC-UHFFFAOYSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DPXHITFUCHFTKR-UHFFFAOYSA-L To-Pro-1 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 DPXHITFUCHFTKR-UHFFFAOYSA-L 0.000 description 1
- MZZINWWGSYUHGU-UHFFFAOYSA-J ToTo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 MZZINWWGSYUHGU-UHFFFAOYSA-J 0.000 description 1
- -1 Y There are O-PRO-1 Chemical compound 0.000 description 1
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 1
- JSBNEYNPYQFYNM-UHFFFAOYSA-J YoYo-3 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=CC=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC(=[N+](C)C)CCCC(=[N+](C)C)CC[N+](C1=CC=CC=C11)=CC=C1C=CC=C1N(C)C2=CC=CC=C2O1 JSBNEYNPYQFYNM-UHFFFAOYSA-J 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XVLXYDXJEKLXHN-UHFFFAOYSA-M dioc6 Chemical compound [I-].O1C2=CC=CC=C2[N+](CCCCCC)=C1C=CC=C1N(CCCCCC)C2=CC=CC=C2O1 XVLXYDXJEKLXHN-UHFFFAOYSA-M 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- BUBBEHCXSMCYNY-UHFFFAOYSA-N erythrin Natural products CC1=CC(O)=CC(O)=C1C(=O)OC1=CC(C)=C(C(=O)OCC(O)C(O)CO)C(O)=C1 BUBBEHCXSMCYNY-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- XJCQPMRCZSJDPA-UHFFFAOYSA-L trimethyl-[3-[4-[(e)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]pyridin-1-ium-1-yl]propyl]azanium;diiodide Chemical compound [I-].[I-].S1C2=CC=CC=C2N(C)\C1=C\C1=CC=[N+](CCC[N+](C)(C)C)C=C1 XJCQPMRCZSJDPA-UHFFFAOYSA-L 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. (a)白血球(WBC)細胞膜への傷害を最小限に抑えながらも溶解成分が赤 血球(RBC)を溶解する、RBC 溶解成分、有核赤血球(NRBC)および損傷 WBC の 生体核を染色する生体核染色試薬成分から成る試薬系を血液サンプルのアリコー トと混和する、 (b)混和したアリコートを、実質的に一時に一細胞ずつ、光学的に励起さ れている領域を通過させる、 (c)パラメーターとして蛍光(FL)並びに第一および第二レンジ散乱角度 の両方における散乱光のうち少なくとも一つのシグナルを得る、 (d)検定される該シグナルは第二散乱シグナル閾値よりも大きく、同時に 該シグナルは第一散乱シグナル閾値あるいはFL 閾値のいずれかよりも大きくな ければならず、ここで閾値は得られたシグナル中の見かけの FL ノイズシグナル を除き、NRBC 群シグナルは含むように設定されているロジックにシグナルを適 合させることにより、得られたシグナルを検定する、 (e)得られ、検定されたシグナルからの FL および散乱 光強度シグナルの三次元プロットを構築する、及び (f)構築した三次元プロットおよび検定されたシグナルから WBC、NRBC、 損傷 WBC、 WBC サブクラス(WBC/Diff)を分類し、および各クラスおよびサブ クラスの細胞数を測定することから成る、フローサイトメトリーによるサンプル 中の NRBC,損傷 WBC および WBC を分類する方法。 2. WBC/Diff を分類する前に、測定された NRBC 数を測定された WBC 数から 差し引く請求項1の方法。 3. 散乱角度の第一レンジが約0゜から1゜である請求項1の方法。 4. 第一散乱パラメーターが軸方向光損失(ALL)である請求項1の方法。 5. ALL が約0゜から約1゜の角度で得られる請求項4の方法。 6. 得られたシグナルパラメーターの一つが軸方向光損失(ALL)を含む請求項 1の方法。 7. 核染料がヨウ化プロピジウム(PI)、エチジウムブロマイド(EBr)、エチ ジウムホモダイマー−1(EthD-1) ,エチジウムホモダイマー−2(EthD-2)お よびジエチレントリアミン(DTA)から成る生体染料の群より選択する請求項1 の方法。 8. 得られた散乱パラメーターの一つが前方角散乱(FSC)である請求項1の方 法。 9. さらに、蛍光標識された抗体をサンプルに加え、抗体/サンプル混和物を抗 体がその表面抗原結合対と結合するのに十分な時間インキュベートするステップ をステップ(a)の前に含む請求項2の方法。 10. (a)白血球(WBC)細胞膜および WBC 表面抗原への傷害を最小限に抑えな がらも溶解成分が赤血球(RBC)を溶解する、赤血球(RBC)溶解成分、有核赤血 球(NRBC)および損傷 WBCの生体核を染色する生体核染料成分から成る試薬系を 血液サンプルのアリコートと混和する、 (b)混和したサンプルの一部を、実質的に一時に一細胞ずつ、光学的に励 起されている領域を通過させる、 (c)パラメーターとして、蛍光(FL)および散乱角のレンジが約 0゜か ら約 1゜および約 3゜から 10゜から成る散乱光のうち少なくとも1つのシグ ナルを得る、 (d)検定されるシグナルは 3゜から 10゜の散乱シグナル閾値よりも大き く、同時に該シグナルは 0゜から約 1゜のシグナル閾値あるいは FL 閾値のい ずれかよりも大きくなければな らず、ここで閾値は得られたシグナル中の見かけの FL ノイズシグナルを除き、 NRBC 群シグナルは含むように設定されているロジックにシグナルを適合させて 、得られたシグナルを検定する、 (e)得られ、検定されたシグナルからの FL および散乱光強度シグナルの 三次元プロットを構築する、及び (f)構築した三次元プロットおよび検定されたシグナルから WBC、 NRBC 、損傷 WBC、WBC サブクラス(WBC/Diff)を分類し、およびそれぞれの細胞数 を測定する ことから成る、フローサイトメトリーによるサンプル中の NRBC,損傷 WBC、WBC および WBC サブクラスを分類する方法。 11. 核染料をヨウ化プロピジウム(PI)、エチジウムブロマイド(EBr)、エチ ジウムホモダイマー−1(EthD-1) ,エチジウムホモダイマー−2(EthD-2)お よびジエチレントリアミン(DTA)から成る群より選択する請求項 10 の方法。 12. さらに、蛍光標識された抗体をサンプルに加え、抗体/サンプル混和物を 抗体がその表面抗原結合対と結合するのに十分な時問インキュベートするステッ プをステップ(a)の前に含む請求項 10 の方法。 13. WBC/Diff を測定する前に、測定された NRBC 数を測定された WBC 測定 数から差し引く請求項 10 の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57442495A | 1995-12-15 | 1995-12-15 | |
US08/574,424 | 1995-12-15 | ||
PCT/US1996/020466 WO1997021994A1 (en) | 1995-12-15 | 1996-12-13 | Method for simultaneous analysis of cell viability, nucleated red blood cells and white blood cell differential |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000501838A true JP2000501838A (ja) | 2000-02-15 |
JP2000501838A5 JP2000501838A5 (ja) | 2004-10-21 |
JP4279900B2 JP4279900B2 (ja) | 2009-06-17 |
Family
ID=24296069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52228797A Expired - Lifetime JP4279900B2 (ja) | 1995-12-15 | 1996-12-13 | 細胞生存率、有核赤血球、および白血球分類の同時分析方法 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0866960B1 (ja) |
JP (1) | JP4279900B2 (ja) |
AT (1) | ATE472725T1 (ja) |
CA (1) | CA2240158C (ja) |
DE (1) | DE69638209D1 (ja) |
ES (1) | ES2347110T3 (ja) |
WO (1) | WO1997021994A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010092784A1 (ja) * | 2009-02-13 | 2010-08-19 | 三井造船株式会社 | 蛍光検出装置及び蛍光検出方法 |
WO2010092785A1 (ja) * | 2009-02-13 | 2010-08-19 | 三井造船株式会社 | 蛍光検出装置及び蛍光検出方法 |
JP2012525589A (ja) * | 2009-04-27 | 2012-10-22 | アボット・ラボラトリーズ | 自動血液分析器において、レーザーからの前方散乱を用いることによる、赤血球細胞を白血球細胞から判別する方法 |
JP2014520253A (ja) * | 2011-05-04 | 2014-08-21 | アボット・ラボラトリーズ | 好塩基球分析システムおよび方法 |
JP2014520251A (ja) * | 2011-05-04 | 2014-08-21 | アボット・ラボラトリーズ | 白血球分析システムおよび方法 |
US9778163B2 (en) | 2011-05-04 | 2017-10-03 | Abbott Laboratories | Nucleated red blood cell analysis system and method |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5917584A (en) * | 1997-11-21 | 1999-06-29 | Coulter International Corp. | Method for differentiation of nucleated red blood cells |
WO2014099629A1 (en) * | 2012-12-21 | 2014-06-26 | The Regents Of The University Of California | Rapid blood testing platform for use with mobile electronic devices |
CN105699635A (zh) * | 2016-01-28 | 2016-06-22 | 深圳市帝迈生物技术有限公司 | 一种简单可靠的血细胞五分类分析方法、系统及装置 |
CN111602046B (zh) * | 2018-04-28 | 2024-01-09 | 深圳迈瑞生物医疗电子股份有限公司 | 一种血液分析仪及分析方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02103464A (ja) * | 1988-06-13 | 1990-04-16 | Becton Dickinson & Co | サンプル中の損傷細胞及びインタクト細胞を識別するための方法 |
JPH08507147A (ja) * | 1993-02-25 | 1996-07-30 | アボツト・ラボラトリーズ | 全血試料を高速溶解するための多目的試薬系 |
JP2938976B2 (ja) * | 1994-12-15 | 1999-08-25 | アボツト・ラボラトリーズ | 有核赤血球の迅速な同時分析方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047321A (en) * | 1988-06-15 | 1991-09-10 | Becton Dickinson & Co. | Method for analysis of cellular components of a fluid |
DE69329353T2 (de) | 1992-03-05 | 2001-01-04 | Becton Dickinson And Co., Franklin Lakes | Verfahren zur Herstellung und Analyse von Leukozyten in Vollblut unter Verwendung der Durchflusszytometrie |
-
1996
- 1996-12-13 AT AT96945254T patent/ATE472725T1/de not_active IP Right Cessation
- 1996-12-13 CA CA002240158A patent/CA2240158C/en not_active Expired - Fee Related
- 1996-12-13 DE DE69638209T patent/DE69638209D1/de not_active Expired - Lifetime
- 1996-12-13 EP EP96945254A patent/EP0866960B1/en not_active Expired - Lifetime
- 1996-12-13 WO PCT/US1996/020466 patent/WO1997021994A1/en active Application Filing
- 1996-12-13 ES ES96945254T patent/ES2347110T3/es not_active Expired - Lifetime
- 1996-12-13 JP JP52228797A patent/JP4279900B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02103464A (ja) * | 1988-06-13 | 1990-04-16 | Becton Dickinson & Co | サンプル中の損傷細胞及びインタクト細胞を識別するための方法 |
JPH08507147A (ja) * | 1993-02-25 | 1996-07-30 | アボツト・ラボラトリーズ | 全血試料を高速溶解するための多目的試薬系 |
JP2938976B2 (ja) * | 1994-12-15 | 1999-08-25 | アボツト・ラボラトリーズ | 有核赤血球の迅速な同時分析方法 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010092784A1 (ja) * | 2009-02-13 | 2010-08-19 | 三井造船株式会社 | 蛍光検出装置及び蛍光検出方法 |
WO2010092785A1 (ja) * | 2009-02-13 | 2010-08-19 | 三井造船株式会社 | 蛍光検出装置及び蛍光検出方法 |
KR101248504B1 (ko) | 2009-02-13 | 2013-04-02 | 미쯔이 죠센 가부시키가이샤 | 형광 검출 장치 및 형광 검출 방법 |
US8642976B2 (en) | 2009-02-13 | 2014-02-04 | Mitsui Engineering & Shipbuilding Co., Ltd. | Fluorescence detecting device and fluorescence detecting method |
US8772739B2 (en) | 2009-02-13 | 2014-07-08 | Mitsui Engineering & Shipbuilding Co., Ltd. | Fluorescence detection device and fluorescence detection method |
JP2012525589A (ja) * | 2009-04-27 | 2012-10-22 | アボット・ラボラトリーズ | 自動血液分析器において、レーザーからの前方散乱を用いることによる、赤血球細胞を白血球細胞から判別する方法 |
JP2014520253A (ja) * | 2011-05-04 | 2014-08-21 | アボット・ラボラトリーズ | 好塩基球分析システムおよび方法 |
JP2014520251A (ja) * | 2011-05-04 | 2014-08-21 | アボット・ラボラトリーズ | 白血球分析システムおよび方法 |
US9778163B2 (en) | 2011-05-04 | 2017-10-03 | Abbott Laboratories | Nucleated red blood cell analysis system and method |
US9778162B2 (en) | 2011-05-04 | 2017-10-03 | Abbott Laboratories | White blood cell analysis system and method |
US9810618B2 (en) | 2011-05-04 | 2017-11-07 | Abbott Laboratories | Basophil analysis system and method |
US10481072B2 (en) | 2011-05-04 | 2019-11-19 | Abbott Laboratories | Nucleated red blood cell analysis system and method |
US10481073B2 (en) | 2011-05-04 | 2019-11-19 | Abbott Laboratories | Basophil analysis system and method |
US10481071B2 (en) | 2011-05-04 | 2019-11-19 | Abbott Laboratories | White blood cell analysis system and method |
Also Published As
Publication number | Publication date |
---|---|
ES2347110T3 (es) | 2010-10-25 |
EP0866960B1 (en) | 2010-06-30 |
WO1997021994A1 (en) | 1997-06-19 |
DE69638209D1 (de) | 2010-08-12 |
ATE472725T1 (de) | 2010-07-15 |
CA2240158A1 (en) | 1997-06-19 |
JP4279900B2 (ja) | 2009-06-17 |
EP0866960A1 (en) | 1998-09-30 |
CA2240158C (en) | 2004-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5879900A (en) | Method for simultaneous analysis of cell viability, nucleated red blood cells and white blood cell differentials | |
CA2207396C (en) | Method for rapid and simultaneous analysis of nucleated red blood cells | |
US4727020A (en) | Method for analysis of subpopulations of blood cells | |
US7625712B2 (en) | Method for a fully automated monoclonal antibody-based extended differential | |
CA1309328C (en) | Method of classifying leukocytes by flow cytometry and reagents used in the method | |
JP4433611B2 (ja) | 有核の赤血球の識別方法 | |
US5296378A (en) | Method for classifying leukocytes by flow cytometry | |
US8137975B2 (en) | Method for a rapid antibody-based analysis of platelet populations | |
US5776709A (en) | Method for preparation and analysis of leukocytes in whole blood | |
US5179026A (en) | Method of classifying leukocytes by flow cytometry and reagents used in the method | |
US5874311A (en) | Method for differentiation of reticulocytes in blood | |
US5840515A (en) | Erythrocyte lysis reagent, and its use in methods for isolating and differentiating leucocytes | |
JP4279900B2 (ja) | 細胞生存率、有核赤血球、および白血球分類の同時分析方法 | |
WO1997021994A9 (en) | Method for simultaneous analysis of cell viability, nucleated red blood cells and white blood cell differential | |
CA1309327C (en) | Reagent and method for classifying leukocytes by flow cytometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060920 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20070605 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070829 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080728 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20080728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080829 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090224 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090313 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120319 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130319 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140319 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |